TLP0-001

TLP0-001 (marketed under the **Vaccell** brand platform) is an autologous dendritic cell (DC) vaccine developed by the Japanese biotechnology company **Tella Co., Ltd.** in collaboration with academic institutions such as Wakayama Medical University and Nagasaki University Hospital. This personalized immunotherapy involves harvesting a patient's own monocyte-derived dendritic cells through apheresis, which are then matured ex vivo—often using the streptococcal preparation **OK-432 (Picibanil)** as an adjuvant to stimulate interleukin-12 production—and pulsed with synthetic peptides derived from two tumor-associated antigens (TAAs): **Mucin 1 (MUC1)** and **Wilms' tumor protein 1 (WT1)**. Upon re-administration, typically via intradermal or subcutaneous injection, these professional antigen-presenting cells activate and expand MUC1- and WT1-specific cytotoxic T-lymphocytes (CTLs) that target and lyse cancer cells overexpressing these proteins. While the therapy reached a pivotal Phase III clinical trial for advanced pancreatic ductal adenocarcinoma in Japan, commercial development was essentially halted following the bankruptcy of Tella Co., Ltd. in August 2022.

Brand names

Vaccell

Other names

autologous dendritic cells pulsed with mucin 1 + wilms' tumor 1 peptidesMUC-1/WT1 peptide-primed autologous dendritic cellsWT1/MUC1-DCWT1 and MUC1 peptide-pulsed dendritic cell vaccineWT-1 and MUC1 peptide-pulsed dendritic cell vaccineWT 1 and MUC1 peptide-pulsed dendritic cell vaccineMUC1/WT1 peptide-primed autologous dendritic cells